The most expensive misunderstanding in this category is the belief that putting RFID on a medical device satisfies unique device identification requirements.
It does not. Not in the US, not in the EU, and not in the way most buyers assume.
This is not a reason to avoid RFID — it is a reason to understand what each mechanism is for. RFID and UDI solve adjacent problems, and a deployment built on the assumption that one substitutes for the other will fail a regulatory review while having spent its entire budget.
This article is about that boundary. It is written for people specifying systems, not for regulatory counsel; confirm the specifics against the current regulation and your own compliance function.
A unique device identifier is a code with a defined structure, assigned under a regulatory framework, that appears on a device label or on the device itself, and whose data is submitted to a central database.
The structure has two parts:
UDI-DI — Device Identifier. Fixed for a given device model or version. It identifies what the device is.
UDI-PI — Production Identifier. Variable: lot or batch, serial number, expiry date, date of manufacture. It identifies which one.
The regulatory requirement is that this code appears in a form that can be read by a person or a machine — and in practice this means a barcode, or for certain reusable devices, a permanent mark on the device itself.
The critical point for RFID buyers: RFID is a data carrier that can contain the UDI-DI and UDI-PI. It is not, by itself, the compliant marking. The label on the package and, where required, the direct mark on the device are what satisfy the regulation. The tag is an additional, optional channel.
This is where surgical instruments diverge from single-use devices, and it is the part most RFID proposals get wrong.
For devices intended to be used more than once and reprocessed between uses, regulators require the UDI to be directly marked on the device itself — not only on its packaging. The logic is straightforward: the packaging is discarded after first use, so a package-only identifier is unavailable for the remaining life of the device, which may be years and hundreds of reprocessing cycles.
Direct marking means the mark must:
Survive the intended life of the device
Survive reprocessing — washing, disinfection, sterilization
Remain legible after repeated handling
Not create a cleaning or bioburden problem — no crevices, no peeling
Typical implementations are laser marking, dot-peen marking, or in some cases a durable etched or moulded feature.
This has a direct consequence for RFID: if you are attaching a tag to a reusable instrument, the direct mark and the tag are two separate things, and the direct mark is the one that is mandatory. The tag can carry the same identifier in electronic form, which makes it readable without line of sight and without orienting the instrument — genuinely useful, and not a substitute.
Used correctly, RFID contributes in four places:
1. Reading without line of sight. A direct mark on a haemostat must be found and oriented to be read. A tag is read by proximity. In a department processing thousands of instruments, this difference is the entire labour argument.
2. Linking the device to its reprocessing record. The identifier is the key. With it, each sterilization cycle, inspection finding and repair event attaches to a specific serialized device. Without it, history is attached to a model number or to nothing.
3. Supporting the production identifier. Serial-level tracking of individual instruments — which is what a UDI-PI requires — is exactly what a serialized tag provides naturally.
4. Data integrity. A tag with protected memory or authentication is harder to duplicate than a printed mark, which matters where identifiers drive recall scope or patient notification.
Be explicit about these, because they will come up:
It does not satisfy the labelling requirement. The barcode on the package is still required.
It does not satisfy direct marking. The permanent mark on a reusable device is still required.
It does not populate the database. Submission to the central registry is a regulatory data obligation, performed through the regulator's mechanism — not by the tag vendor, and not by the Hospital.
It does not transfer responsibility. Whoever holds the labelling obligation retains it.
Start from the marking obligation, not the technology. Establish what must be marked, where, and in what form. Then decide what RFID adds.
Use the same identifier in both channels. The tag and the direct mark should resolve to the same device record. Two parallel numbering schemes create a reconciliation burden that outlives the project.
Keep the human-readable mark. Even with tags, a printed or etched identifier is the fallback when a reader fails or a battery dies.
Confirm the tagging does not alter the device. Attaching anything to a medical device can interact with its intended use, its cleaning validation and its manufacturer's instructions. Get the manufacturer's position in writing.
Ask the vendor what their quality system is. A supplier operating under a medical device quality management system is a different proposition from a general RFID vendor, and for devices this matters.
Verify against current regulation and your own compliance function. Requirements differ by jurisdiction, by device class, and by whether the device is reusable, implantable or single-use.
UDI answers: what is this device, and which one is it? — a regulatory question, answered by a code, a mark, and a database submission.
RFID answers: where is this specific device, and what has happened to it? — an operational question, answered by a tag, readers, and a system that maintains history.
They meet at the identifier. Build them to share one, and each does what it is good at.
*Related: HF RFID Medical Device Traceability · Reusable Medical Device Tracking · RFID Surgical Instrument Tracking
Contact: Adam
Phone: +86 18205991243
E-mail: sale1@rfid-life.com
Add: No.987,Innovation Park,Huli District,Xiamen,China
Adam